about
Raf kinases in cancer-roles and therapeutic opportunitiesTargeting the MAPK-RAS-RAF signaling pathway in cancer therapySelective requirement for Mediator MED23 in Ras-active lung cancer.Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases.Targeting the RAS pathway in melanoma.Modeling anaplastic thyroid carcinoma in the mouse.BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.Challenges in the delivery of therapies to melanoma brain metastases.Specifically targeting ERK1 or ERK2 kills melanoma cellsGlomerulonephritis and granulomatous vasculitis in kidney as a complication of the use of BRAF and MEK inhibitors in the treatment of metastatic melanoma: A case report.Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion.Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma AlMechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
P2860
Q28237793-155F7659-638F-4D5C-84AC-2C1F826ED6E8Q36278239-FA647D61-AD51-45FD-8B49-8E89634A84A8Q36339876-FDC64EE7-CE68-418D-BA28-0B83AC0C8022Q36503052-A0CC6007-2F0A-41BD-837A-C795A6BD0C0DQ37137004-DA45A7C3-7D68-4178-8EB2-55493E7BE3E9Q38270915-FD35423B-8873-4F7C-A766-88EF67B44348Q39212469-159F9679-4D92-46F3-93F4-70C0DA671944Q39331752-33A326D0-ECDE-48A0-855A-821EBF5B6A16Q39406388-5914174D-AB6F-4635-ACF8-4C5C340C14A8Q41045314-A10729E5-F7F9-4D4B-AC1D-33D7F0375A7FQ42206973-46E5ACD1-8CB1-4B13-8908-D9FDDD9C398CQ43215055-19198C75-99C4-47C7-9A6F-B8E1E47DC293Q54355019-89834A3E-EA2A-43B7-B4D9-38EB2EC5E7EEQ58547833-89CAB836-C98C-44D4-9B61-BB51AB78FF14
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Biological challenges of BRAF inhibitor therapy
@en
Biological challenges of BRAF inhibitor therapy.
@nl
type
label
Biological challenges of BRAF inhibitor therapy
@en
Biological challenges of BRAF inhibitor therapy.
@nl
prefLabel
Biological challenges of BRAF inhibitor therapy
@en
Biological challenges of BRAF inhibitor therapy.
@nl
P2860
P1433
P1476
Biological challenges of BRAF inhibitor therapy
@en
P2093
Igor Puzanov
Patrick Burnett
P2860
P304
P356
10.1016/J.MOLONC.2011.01.005
P577
2011-02-16T00:00:00Z